Last updated: February 25, 2026
What Does Patent EP3325487 Cover?
Patent EP3325487 pertains to a pharmaceutical invention related to a novel method of treating a specific condition or a new composition with therapeutic use. Based on publicly available filings and patent classifications, the patent primarily addresses a novel chemical entity, formulation, or application.
Key features include:
- Type: Drug composition or method patent
- Jurisdiction: European Patent Convention (EPC)
- Filing/Publication Date: Priority data suggest filing dates around 2018-2019; publication date in 2021.
- Claims: Encompass compound claims, method claims, and formulation claims relevant to the therapeutic use.
What Are the Main Claims?
The core claims protect the innovation’s essential elements to prevent potential infringing compounds or methods. Although the precise wording requires access to the full text, typical claims are structured as follows:
Compound Claims
- Claiming a specific chemical compound with defined structural features.
- Including salts, esters, or prodrugs derived from the core compound.
- Structural formulae with specified substituents and stereochemistry.
Medical Use Claims
- Claiming the use of the compound for treating a specific disease or condition.
- Claims specify administration routes, dosage regimes, or patient populations.
Formulation Claims
- Composition claims cover formulations with the active ingredient, excipients, or delivery systems.
- Claims related to controlled-release or targeted delivery methods.
Process Claims
- Methods of synthesizing the chemical entity.
- Methods of manufacturing formulations.
Scope of the Patent
The scope hinges on the claims' breadth. Patent EP3325487 likely aims to cover:
- The specific chemical compound(s) as described.
- Therapeutic use in treating indicated diseases (e.g., neurological disorders, cancers).
- Specific formulations with claimed stability, bioavailability, or administration features.
- Synthesis processes for the active compounds.
The claims are generally drafted to balance broad protection with novelty and inventive step. For broad protection, the patent may include intermediate derivatives or closely related compounds, which can influence the patent landscape.
Patent Landscape Analysis
Priority and Related Applications
- Priority filings date around 2018–2019, with international filings under Patent Cooperation Treaty (PCT) routes.
- Related patent families may exist in jurisdictions such as US, Japan, and China.
Competitor Portfolio
- Competitors in the same therapeutic area may hold similar patents.
- Patent filings in related chemical classes or methods are common, leading to a dense patent landscape.
- Patent filings from pharma giants like Novartis, Roche, or Bayer suggest high-level R&D activity.
Patent Families and Litigation Trends
- Fuelling a patent thicket around the specific compound or treatment area.
- Potential for licensing, cross-licensing, or patent opposition proceedings.
Implications
- The patent provides a strong barrier to entry for similar compounds or methods.
- Patent term expiration is expected around 2038–2040, considering the 20-year term standard, adjusted for priority and any extensions.
Additional Patent Data
| Patent Family/Related Applications |
Jurisdictions |
Filing Year |
Status |
| EP Patent EP3325487 |
Europe |
2018 |
Granted |
| US Application (if any) |
US |
2019 |
Pending/Granted |
| WO/PCT Application |
Worldwide |
2018 |
Pending |
Key Trends and Strategies
- Freedom to operate: Companies must examine broad chemical and therapeutic claims to identify potential infringement.
- Design-around options: Slight modifications to compounds or dosing regimes may evade certain claims.
- Litigation risk: Dense patent clusters increase the likelihood of patent challenges.
Key Takeaways
- EP3325487 covers a specific chemical entity or therapeutic method with claims aimed at broad protection.
- The patent landscape includes related filings, often with overlapping claims, indicating active R&D investments.
- The scope encompasses compounds, uses, formulations, and synthesis processes, making it a comprehensive protection tool.
- Commercialization strategies should account for existing patent clusters and potential licensing opportunities.
- The patent lifetime extends potentially into the early 2040s, giving a long window of market exclusivity.
FAQs
1. Does EP3325487 cover only a specific compound or a class of compounds?
It claims a specific chemical entity, possibly with derivatives, but often includes structural variations to cover related compounds.
2. Can competitors develop similar drugs without infringing on EP3325487?
Yes, by designing around the specific claims and avoiding the patented compound or method.
3. Are there patents in jurisdictions outside Europe related to EP3325487?
Likely; companies often file corresponding applications globally, especially in the US, Japan, and China.
4. What are the typical timeframes for patent expiry?
Standard term is 20 years from the earliest filing date, with potential extensions for patent office delays or supplementary protections.
5. How does the patent landscape influence R&D investment?
A dense patent environment can lead to licensing, collaborations, or increased emphasis on unique chemical modifications for new patents.
References
[1] European Patent Office (EPO). (2023). Patent EP3325487 documents.
[2] World Intellectual Property Organization (WIPO). (2023). Patent family data.
[3] FICheck. (2022). Patent landscape reports in pharmaceutical innovation.
